FDA Delays Decision on Actos Replacement

By: Seeger Weiss on May 3, 2012

Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin.

Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin. Alogliptin, a diabetes medication, was expected to be the successor to Takeda’s top-selling drug Actos. Before Takeda lost its patent protection on Actos, the type-2 diabetes treatment had been linked to an increased risk of bladder cancer in studies. In response, the FDA issued a warning to doctors who prescribed Actos to patients.

Seeger Weiss LLP, a national plaintiffs’ law firm, has been actively investigating the link between Actos and bladder cancer. If you believe you or someone you know developed bladder cancer as a result of taking Actos, the firm’s drug injury practice will review your case for free. Contact them here.

Free Case Evaluation Fill out the form for a Free Case Evaluation within 24 hours

By submitting this form I agree to the terms of SeegerWeiss.com Disclaimer and Privacy Policy

Handling Cases Nationwide

we support

Sign Up to our Consumer Alerts Newletter
Free Case Evaluation Fill out the form for a Free Case Evaluation within 24 hours

By submitting this form I agree to the terms of SeegerWeiss.com Disclaimer and Privacy Policy

×